TELA News and Press, TELA Bio Inc. From 05/09/24

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights ...

MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2024 financial results on Thu...

MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue...

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strat...

2024-04-06 03:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-21 19:38:03 ET TELA Bio, Inc. (TELA) Q4 2023 Earnings Conference Call March 21, 2024, 04:30 PM ET Company Participants Louisa Smith - Vice President, Gilmartin Group Antony Koblish - Co-Founder, President and Chief Executive Officer Roberto Cuca - Chief O...

2024-03-21 16:13:43 ET More on TELA Bio TELA Bio: Looks Like A Buy, But Some Pieces Missing To Make This A Strong Buy TELA Bio launches Liquifix surgical devices in the U.S. Seeking Alpha’s Quant Rating on TELA Bio Historical earnings data for TELA Bio...

MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own an...

2024-03-21 07:59:20 ET More on TELA Bio TELA Bio: Looks Like A Buy, But Some Pieces Missing To Make This A Strong Buy Seeking Alpha’s Quant Rating on TELA Bio Historical earnings data for TELA Bio Financial information for TELA Bio Read the f...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...